Table 1.
Patient Characteristics, Infection Details, Treatment, and Outcomes.
| Age (Years); Sex; Race | Active IDU | Infection Type | Organism (s) in Blood Culture | Source | Source Control Achieved | Pre-DAL Antibiotic(s); Total Days | Dalba. Dose(s) | DAL Doses Received/Intended | Intended DAL Course (Days) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 24; F; Cauc. | Yes | Definitive IE | MRSA, α and γ hemolytic Streptococci, Bacillus cereus | Unknown | NA | VAN; 21 | 1500 mg | 1/2 | 42 | LTFU |
| 24; F; Cauc. | Yes | Possible IE | MSSA | Unknown | NA | OXA, CFZ; 21 | 1500 mg | 1/2 | 42 | Cure |
| 27; M; AA | Yes | BSI | Staphylococcus lugdunensis | Unknown | NA | VAN; 3 | 1500 mg | 1/2 | 14 | LTFU |
| 29; M; Cauc. | Yes | BSI | MRSA | OM | No | VAN, SAM; 4 | 1500 mg | 1/2 | 42 | Failure |
| 35; M; Cauc. | No | BSI | MSSA, GAS, CoNS | SSTI | NA | VAN, CFZ; 4 | 1500 mg | 1/1 | 14 | Failure (death) |
| 36; M; Cauc. | Yes | Definitive IE | Streptococcus mitis | Unknown | NA | CRO, GEN; 11 | 1500 mg | 1/1 | 14 | LTFU |
| 36; M; Cauc. | Yes | BSI | MRSA | PNA/ empyema | Yes | VAN; 30 | 1500 mg | 1/1 | 42 | LTFU |
| 38; M; Cauc. | No | BSI | MRSA | Unknown | NA | VAN; 2 | 1500 mg; 1000 mg | 2/2 | 28 | Cure |
| 38; F; AA | No | BSI | GAS | SSTI | Yes | VAN; 6 | 1500 mg | 1/1 | 14 | Cure |
| 44; M; Cauc. | Yes | Possible IE | MRSA, Klebsiella pneumonia, Candida albicans and tropicalis, | CLABSI | Yes | VAN, DAP; 27 | 1500 mg | 1/1 | 42 | Failure (death) |
| 50; M; Cauc. | Yes | Dissem. MRSA | sterile | SSTI | Yes | VAN; 13 | 1500 mg; 1500 mg | 2/2 | 28 | Failure |
| 50; M; AA | Yes | BSI | MRSA | SSTI | No | VAN; 6 | 1500 mg | 1/1 | 14 | Cure |
| 50; F; Cauc. | Yes | BSI | MSSA | Unknown | NA | VAN, CFZ; 23 | 1000 mg; 500 mg | 2/2 | 42 | Failure |
| 51; F; Cauc. | Yes | BSI | MSSA | Unknown | NA | VAN, CFZ; 11 | 1500 mg | 1/1 | 14 | Cure |
| 51; M; Cauc. | Yes | BSI | MRSA | OM | Yes | VAN 11 | 1500 mg; 1000 mg | 2/2 | 28 | Cure |
| 55; F; AA | No | BSI | MRSA | CLABSI | Yes | VAN; 8 | 1500 mg; 1500 mg | 2/3 | 28 | Cure |
| 57; M; Cauc. | No | BSI | Staphylococcus epidermidis, Klebsiella pneumoniae | Unknown | NA | VAN; 12 | 1500 mg | 1/1 | 14 | Cure |
| 66; M; AA | No | BSI | MRSA, Enterococcus feacalis Acinetobacter baumanni, Pseudomonas aeruginosa, Candida albicans, | Unknown | NA | VAN; 8 | 1500 mg | 1/1 | 14 | Failure (death) |
AA, African American; Cauc., Caucasian; CFZ, cefazolin; CLABSI, central-line associated blood stream infection; CoNS, coagulase-negative Staphylococcus; CRO, ceftriaxone; DAL, dalbavancin; DAP, daptomycin; Dissem., disseminated; F, female; GAS, group A Streptococcus; GEN, gentamycin; IDU, injection drug use; IE, infective endocarditis; LTFU, lost to follow-up; M, male; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; OM, osteomyelitis; OXA, oxacillin; PNA, pneumonia; SAM, ampicillin–sulbactam; SSTI, skin and soft-tissue infections; VAN, vancomycin.